依达拉奉对急性脑梗死患者自由基清除的临床研究

目的 探讨依达拉奉清除自由基治疗急性脑梗死的临床疗效.方法 脑梗死患者60例,随机分为治疗组和对照组,两组均常规脱水、降颅压、控制血压等,治疗组用生理盐水250 ml+依达拉奉30 mg静脉滴注,2次/d,连续使用14 d;对照组用生理盐水250 ml,静脉滴注,2次/d,连续使用14d.两组分别于治疗前和治疗后第14 d进行神经功能缺失程度和日常生活活动能力评分(ADL),测定血清超氧化物歧化酶(SOD).结果 治疗组与对照组比较,治疗第14天患者的神经功能缺失程度(7.5±5.4)分与(15.9±7.9)分,P＜0.05]、ADL得分(58.32±11.57)分与(43.73±12.48)分,P＜0.05]和血清SOD(157.25±21.81)mmol/L与(127.08±13.14)mmol/L,P＜0.05]都得到改善,差异均有统计学意义.结论 依达拉奉治疗急性脑梗死可以提高机体清除自由基能力,促进神经功能恢复.

Clinical study in effect of edaravone on free radical scavenging in patients with acute cerebral infarction

Objective To investigate the clinical effect of edaravone on free radical damage after acute stroke. Methods The 60 patients with acute stroke were randomly divided into therapy group and control group. Both the groups were treated with routine approaches of dehydration, intracranial pressure reducing and blood pressure control. The treatment with balanced saline 250 ml plus edaravone 30 mg, intravenously infusion twice a day, was adopted in therapy group, while the control group received balanced saline 250 ml only, the treatment lasted for 14 days. Before and 14 days after treatment, the neurologic impairment analysis, activity of daily living scale (ADL) and serum superoxide dismutase (SOD) were checked. Results Compared with control group, after 14 dtreatment, the improvements in neurologic impairment analysis (7.5±5.4 vs. 15.9±7.9, P＜0.05),ADL (58.32±11.57 vs. 43.73± 12.48, P＜0.05) and SOD(157.25±21.81)mmol/L vs. (127.08 ± 13. 14)mmol/L, P＜0. 05] occurred in therapy group. Conclusions Edaravone could increase the ability of cleaning free radicals and promoting function of nerves recovery.